Chiasma Inc  

(Public, NASDAQ:CHMA)   Watch this stock  
Find more results for CHMA
+0.05 (3.23%)
Feb 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.50 - 1.60
52 week 1.25 - 2.95
Open 1.55
Vol / Avg. 7,885.00/94,545.00
Mkt cap 39.01M
P/E     -
Div/yield     -
EPS -1.17
Shares 24.38M
Beta     -
Inst. own 66%
Mar 14, 2018
Q4 2017 Chiasma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -34.36% -48.92%
Return on average equity -38.67% -53.48%
Employees 17 -
CDP Score - -


460 Totten Pond Rd Ste 530
WALTHAM, MA 02451-1944
United States - Map
+1-617-9285300 (Phone)
+1-339-2003009 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Officers and directors

David M. Stack Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark J. Fitzpatrick President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
Age: 54
Bio & Compensation  - Reuters
Drew Enamait Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller
Age: 42
Bio & Compensation  - Reuters
Roni Mamluk Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Todd Foley Independent Director
Age: 45
Bio & Compensation  - Reuters
Bard J. Geesaman M.D. Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Scott Minick Independent Director
Age: 65
Bio & Compensation  - Reuters
John A. Scarlett M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters